Summary:
– ISM9682 is an oral small-molecule inhibitor designed to target KIF18A, a protein that promotes chromosomal instability in cancer cells.
– The inhibitor has a unique macrocyclic structure and was created using Insilico’s Chemistry42 generative AI platform.
– ISM9682 is specifically aimed at treating advanced solid tumors.
Author’s Take:
Insilico’s novel creation, ISM9682, marks a significant step in the fight against solid tumors by targeting KIF18A with a unique approach. With its distinctive macrocyclic structure designed through artificial intelligence, this inhibitor opens new possibilities for combating cancer cells with chromosomal instability. This innovative development showcases the power of AI in advancing cancer treatment research.
Click here for the original article.